The use of Infliximab (IFX [Remicade]), a human/mouse chimeric monoclonal antibody targeting tumor necrosis factor alpha (TNF-α) (19), is an effective treatment for patients with refractory moderate to severe CD. The gene discussed is TNF; the disease is Cowden disease.